Literature DB >> 22943011

Gastrointestinal stromal tumor.

Xiaohui Zhao, Changjun Yue.   

Abstract

Gastrointestinal stromal tumor has received a lot of attention over the last 10 years due to its unique biologic behavior, clinicopathological features, molecular mechanisms, and treatment implications. GIST is the most common mesenchymal neoplasm in the gastrointestinal tract and has emerged from a poorly understood and treatment resistant neoplasm to a well-defined tumor entity since the discovery of particular molecular abnormalities, KIT and PDGFRA gene mutations. The understanding of GIST biology at the molecular level promised the development of novel treatment modalities. Diagnosis of GIST depends on the integrity of histology, immunohistochemistry and molecular analysis. The risk assessment of the tumor behavior relies heavily on pathological evaluation and significantly impacts clinical management. In this review, historic review, epidemiology, pathogenesis and genetics, diagnosis, role of molecular analysis, prognostic factor and treatment strategies have been discussed.

Entities:  

Keywords:  GIST; Gastrointestinal stromal tumor; KIT mutation; imatinib

Year:  2012        PMID: 22943011      PMCID: PMC3418531          DOI: 10.3978/j.issn.2078-6891.2012.031

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  181 in total

Review 1.  Gastrointestinal stromal tumors and leiomyosarcomas.

Authors:  Steven C Katz; Ronald P DeMatteo
Journal:  J Surg Oncol       Date:  2008-03-15       Impact factor: 3.454

2.  KIT exon 11 codon 557/558 deletion/insertion mutations define a subset of gastrointestinal stromal tumors with malignant potential.

Authors:  Katerina Kontogianni-Katsarou; Euthimios Dimitriadis; Constantina Lariou; Evi Kairi-Vassilatou; Nikolaos Pandis; Agatha Kondi-Paphiti
Journal:  World J Gastroenterol       Date:  2008-03-28       Impact factor: 5.742

3.  An enhanced risk-group stratification system for more practical prognostication of clinically malignant gastrointestinal stromal tumors.

Authors:  Tsuyoshi Takahashi; Kiyokazu Nakajima; Akiko Nishitani; Yoshihito Souma; Seiichi Hirota; Yoshiki Sawa; Toshirou Nishida
Journal:  Int J Clin Oncol       Date:  2007-10-22       Impact factor: 3.402

4.  Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST).

Authors:  Ronald P Dematteo; Jason S Gold; Lisa Saran; Mithat Gönen; Kui Hin Liau; Robert G Maki; Samuel Singer; Peter Besmer; Murray F Brennan; Cristina R Antonescu
Journal:  Cancer       Date:  2008-02-01       Impact factor: 6.860

Review 5.  Optimizing the dose of imatinib for treatment of gastrointestinal stromal tumours: lessons from the phase 3 trials.

Authors:  Shreyaskumar Patel; John R Zalcberg
Journal:  Eur J Cancer       Date:  2008-01-29       Impact factor: 9.162

6.  Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

Authors:  Charles D Blanke; George D Demetri; Margaret von Mehren; Michael C Heinrich; Burton Eisenberg; Jonathan A Fletcher; Christopher L Corless; Christopher D M Fletcher; Peter J Roberts; Daniela Heinz; Elisabeth Wehre; Zariana Nikolova; Heikki Joensuu
Journal:  J Clin Oncol       Date:  2008-02-01       Impact factor: 44.544

7.  A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors.

Authors:  Inigo Espinosa; Cheng-Han Lee; Mi Kyung Kim; Bich-Tien Rouse; Subbaya Subramanian; Kelli Montgomery; Sushama Varma; Christopher L Corless; Michael C Heinrich; Kevin S Smith; Zhong Wang; Brian Rubin; Torsten O Nielsen; Robert S Seitz; Douglas T Ross; Robert B West; Michael L Cleary; Matt van de Rijn
Journal:  Am J Surg Pathol       Date:  2008-02       Impact factor: 6.394

Review 8.  Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours.

Authors:  J Lasota; M Miettinen
Journal:  Histopathology       Date:  2008-02-28       Impact factor: 5.087

9.  Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib.

Authors:  Tammy F Chu; Maria A Rupnick; Risto Kerkela; Susan M Dallabrida; David Zurakowski; Lisa Nguyen; Kathleen Woulfe; Elke Pravda; Flavia Cassiola; Jayesh Desai; Suzanne George; Jeffrey A Morgan; David M Harris; Nesreen S Ismail; Jey-Hsin Chen; Frederick J Schoen; Annick D Van den Abbeele; George D Demetri; Thomas Force; Ming Hui Chen
Journal:  Lancet       Date:  2007-12-15       Impact factor: 79.321

10.  Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study.

Authors:  Claudia Mucciarini; Giulio Rossi; Federica Bertolini; Riccardo Valli; Claudia Cirilli; Ivan Rashid; Luigi Marcheselli; Gabriele Luppi; Massimo Federico
Journal:  BMC Cancer       Date:  2007-12-20       Impact factor: 4.430

View more
  51 in total

1.  Altered expression profile of micrornas in gastric stromal tumor.

Authors:  Jun Xiao; Qi-Xian Wang; You-Qing Zhu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-12-16

2.  Hedgehog signalling pathway activation in gastrointestinal stromal tumours is mediated by primary cilia.

Authors:  Pablo Iruzubieta; Marta Monzón; Tomás Castiella; Teresa Ramírez; Concepción Junquera
Journal:  Gastric Cancer       Date:  2019-07-02       Impact factor: 7.370

3.  MicroRNA-218 inhibits gastrointestinal stromal tumor cell and invasion by targeting KIT.

Authors:  Rong Fan; Jie Zhong; Sichang Zheng; Zhengting Wang; Ying Xu; Shuyi Li; Jie Zhou; Fei Yuan
Journal:  Tumour Biol       Date:  2013-12-29

4.  Stomach GIST presenting as a liver abscess.

Authors:  Farhad Fakhrejahani; David Gemmel; Sudershan K Garg
Journal:  J Gastrointest Cancer       Date:  2014-12

5.  A Large Cystic Variant of Gastro-intestinal Stromal Tumour arising from the Jejunum: A Case Report.

Authors:  Salman Tehran Shaikh; Manish Harinarayan Upwanshi; Tilakdas S Shetty; Smruti R Ghetla; Hussain Gheewala
Journal:  J Clin Diagn Res       Date:  2015-04-01

6.  Pathologic aspects of tumors of gastrointestinal tract in the era of personalized medicine.

Authors:  Jun Wang
Journal:  J Gastrointest Oncol       Date:  2012-09

7.  Laparoscopic versus open resection of gastric gastrointestinal stromal tumors.

Authors:  Zhen-Bo Shu; Li-Bo Sun; Jun-Peng Li; Yong-Chao Li; Da-Yong Ding
Journal:  Chin J Cancer Res       Date:  2013-04       Impact factor: 5.087

8.  Tyrosine kinase inhibitors significantly improved survival outcomes in patients with metastatic gastrointestinal stromal tumour: a multi-institutional cohort study.

Authors:  A Deruchie Tan; K Willemsma; A MacNeill; K DeVries; A Srikanthan; C McGahan; T Hamilton; H Li; C D Blanke; C E Simmons
Journal:  Curr Oncol       Date:  2020-06-01       Impact factor: 3.677

9.  GIST Jinx - A Rare Case of Acute Massive Life Threatening Bleed from a Jejunal Gastro-Intestinal Stromal Tumour.

Authors:  Pranav Honnavara Srinivasan; Joji I Maliekal; Chaganty Saikiran Reddy; Sriharsha Suda
Journal:  J Clin Diagn Res       Date:  2016-03-01

10.  Colorectal sarcoma: more than a gastrointestinal stromal tumor.

Authors:  C Randall Cooper; Brendan F Scully; Steven Lee-Kong
Journal:  Transl Gastroenterol Hepatol       Date:  2018-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.